Hamilton Lane Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Hamilton Lane Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-448	Closed	-$79.2K	–	64
2023 Q1	$79.2K	Hold	448	–	–	0.03%	57
2022 Q4	$173K	Hold	448	–	–	0.06%	58
2022 Q3	$151K	Hold	448	–	–	0.06%	61
2022 Q2	$147K	Hold	448	–	–	0.06%	64
2022 Q1	$196K	Hold	448	–	–	0.04%	72
2021 Q4	$196K	Hold	448	–	–	0.03%	83
2021 Q3	$249K	Hold	448	–	–	0.04%	69
2021 Q2	$230K	Buy	+448	New	+$284K	0.07%	73
2015 Q2	–	Sell	-1,659	Closed	-$600K	–	73
2015 Q1	$600K	Sell	1,659 -555	-25%	-$210K	0.27%	35
2014 Q4	$795K	Sell	2,214 -278	-11%	-$89.5K	0.3%	34
2014 Q3	$753K	Buy	+2,492	New	+$1.02M	0.25%	37

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hamilton Lane Advisors's TVRD Position: Q2 2023 in Review

Hamilton Lane Advisors sold out of Tvardi Therapeutics (TVRD) in Q2 2023, closing a stake of 448 shares — an estimated $79.2K sold.

Hamilton Lane Advisors first reported a position in TVRD in Q3 2014 and held it in 11 quarters. The position peaked at $795K in Q4 2014. 137 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.

Hamilton Lane Advisors reported no remaining Tvardi Therapeutics position as of Q2 2023 after selling out during the quarter.
Hamilton Lane Advisors sold 448 Tvardi Therapeutics shares in Q2 2023, an estimated $79.2K.
Hamilton Lane Advisors first reported a position in Tvardi Therapeutics in Q3 2014 and held it in 11 quarters.
Hamilton Lane Advisors's Tvardi Therapeutics position peaked at $795K in Q4 2014.
137 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.

Based on Hamilton Lane Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.